/FATE
FATE Stock - Fate Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$1.05+0.00%
+$0.00 (+0.00%) • Dec 19
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.25
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.26
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+185.7%upside
Target: $3.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for FATE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.04 – $1.06
TARGET (TP)$3.00
STOP LOSS$0.97
RISK/REWARD1:24.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.35
52W High$1.99
52W Low$0.66
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $13.63M | $63.53M | $96.30M | $55.85M | $31.43M |
| Gross Profit | $13.63M | $-93,654,000 | $82.54M | $50.00M | $-94,189,000 |
| Gross Margin | 100.0% | -147.4% | 85.7% | 89.5% | -299.6% |
| Operating Income | $-210,276,000 | $-190,511,000 | $-308,386,000 | $-216,994,000 | $-128,085,000 |
| Net Income | $-186,262,000 | $-160,928,000 | $-281,721,000 | $-212,151,000 | $-173,387,000 |
| Net Margin | -1366.5% | -253.3% | -292.5% | -379.9% | -551.6% |
| EPS | $-1.64 | $-1.64 | $-2.91 | $-2.24 | $-2.10 |
Company Overview
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
25%
Hold / Neutral
10
63%
Sell / Underperform
2
13%
Analyst Consensus🔴 Bearish
4 Bullish12 Neutral/Bearish
Price Targets
$20
Average Target
↑ 1778.4% Upside
Now
$4
Low
$20
Average
$90
High
Based on 17 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 31st 2025 | H.C. Wainwright | Upgrade | Buy | $5 |
| October 27th 2025 | Wedbush | Upgrade | Outperform | $7 |
| November 18th 2024 | BofA Securities | Upgrade | Neutral | - |
| June 17th 2024 | Piper Sandler | Upgrade | Overweight | $6← $4 |
| March 27th 2023 | Wells Fargo | Resumed | Equal Weight | $6 |
| January 24th 2023 | H.C. Wainwright | Downgrade | Neutral | $7← $115 |
| January 6th 2023 | BMO Capital Markets | Downgrade | Market Perform | $7← $20 |
| January 6th 2023 | Piper Sandler | Downgrade | Neutral | $12← $71 |
| January 6th 2023 | Cowen | Downgrade | Market Perform | - |
| January 6th 2023 | Stifel | Downgrade | Hold | $5.3← $107 |
| January 6th 2023 | Wedbush | Downgrade | Neutral | $7← $42 |
| January 6th 2023 | BofA Securities | Downgrade | Underperform | $4← $72 |
| January 6th 2023 | Truist | Downgrade | Hold | $7← $46 |
| January 3rd 2023 | Guggenheim | Downgrade | Neutral | - |
| December 22nd 2022 | Oppenheimer | Downgrade | Perform | - |
Earnings History & Surprises
FATEBeat Rate
83%
Last 18 quarters
Avg Surprise
+14.8%
EPS vs Estimate
Beats / Misses
15/2
1 met exactly
Latest EPS
$-0.27
Q4 2025
EPS Surprise History
Q1 24
+21.1%
$-0.45vs$-0.57
Q2 24
0.0%
$-0.47vs$-0.47
Q3 24
+29.8%
$-0.33vs$-0.47
Q4 24
+4.8%
$-0.40vs$-0.42
Q1 25
+29.5%
$-0.31vs$-0.44
Q2 25
+17.9%
$-0.32vs$-0.39
Q3 25
+17.1%
$-0.29vs$-0.35
Q4 25
+6.9%
$-0.27vs$-0.29
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 4, 2026 | $-0.27 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.29 | $-0.27 | +6.9% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.35 | $-0.29 | +17.1% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.39 | $-0.32 | +17.9% | ✓ BEAT |
Q1 2025 | Mar 5, 2025 | $-0.44 | $-0.31 | +29.5% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.42 | $-0.40 | +4.8% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.47 | $-0.33 | +29.8% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.47 | $-0.47 | 0.0% | = MET |
Q1 2024 | Feb 26, 2024 | $-0.57 | $-0.45 | +21.1% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.59 | $-0.46 | +22.0% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.58 | $-0.54 | +6.9% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.55 | $-0.19 | +65.5% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.86 | $-0.58 | +32.6% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.93 | $-0.86 | +7.5% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-0.86 | $-0.79 | +8.1% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-0.78 | $-0.68 | +12.8% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-0.68 | $-0.72 | -5.9% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.58 | $-0.57 | +1.7% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $-0.52 | $-0.58 | -11.5% | ✗ MISS |
Latest News
Fate Therapeutics Presents Updated Clinical Data From Its Ongoing Phase 1 Trial Evaluating Its Ft819 Off-The-Shelf iPSC-derived Car T-cell Program In Systemic Lupus Erythematosus And Unveiled New Preclinical Data From Next-Gen. Off-The-Shelf iPSC-Derived Car T-cell Programs For Hematologic Malignancies And Autoimmune Diseases At 2025 American Society Of Hematology Annual Meeting
📈 PositiveBenzinga•Dec 8, 2025, 01:12 PM
Fate Therapeutics Q3 EPS $(0.27) Beats $(0.29) Estimate, Sales $1.741M Beat $1.535M Estimate
📈 PositiveBenzinga•Nov 13, 2025, 01:41 PM
HC Wainwright & Co. Upgrades Fate Therapeutics to Buy, Maintains Price Target to $5
📈 PositiveBenzinga•Oct 31, 2025, 10:54 AM
Wedbush Upgrades Fate Therapeutics to Outperform, Raises Price Target to $7
📈 PositiveBenzinga•Oct 27, 2025, 12:40 PM
Needham Reiterates Hold on Fate Therapeuticsto Hold
➖ NeutralBenzinga•Oct 27, 2025, 09:40 AM
Reported Sunday, Fate Therapeutics Presents FT819 Phase 1 Data Demonstrating Immune Remodeling And Durable Responses In 10 Patients With Systemic Lupus Erythematosus
📈 PositiveBenzinga•Oct 27, 2025, 06:37 AM
Fate Therapeutics Appoints Kamal Adawi As CFO, Effective October 20
➖ NeutralBenzinga•Oct 14, 2025, 12:05 PM
Fate Therapeutics gets RMAT status from FDA for lupus treatment
📈 PositiveSeeking Alpha•Apr 14, 2025, 03:34 PM
Frequently Asked Questions about FATE
What is FATE's current stock price?
Fate Therapeutics, Inc. (FATE) is currently trading at $1.05 per share. The stock has moved +0.00% today.
What is the analyst price target for FATE?
The average analyst price target for FATE is $3.00, based on 1 analyst.
What sector is Fate Therapeutics, Inc. in?
Fate Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is FATE's market cap?
Fate Therapeutics, Inc. has a market capitalization of $0.12 billion, making it a small-cap company.
Does FATE pay dividends?
No, Fate Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABOS
Acumen Pharmaceuticals, Inc.
$2.15
Mkt Cap: $0.1B
ALEC
Alector, Inc.
$1.40
Mkt Cap: $0.1B
CRBP
Corbus Pharmaceuticals Holdings, Inc.
$8.12
Mkt Cap: $0.1B
INO
Inovio Pharmaceuticals, Inc.
$2.28
Mkt Cap: $0.1B
MOLN
Molecular Partners AG
$4.39
Mkt Cap: $0.2B
NKTX
Nkarta, Inc.
$1.79
Mkt Cap: $0.1B
PEPG
PepGen Inc.
$5.42
Mkt Cap: $0.4B
PRLD
Prelude Therapeutics Incorporated
$2.14
Mkt Cap: $0.2B
SAVA
Cassava Sciences, Inc.
$2.17
Mkt Cap: $0.1B
VOR
Vor Biopharma Inc.
$12.41
Mkt Cap: $0.1B
Explore stocks similar to FATE for comparison